# A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines

> **NCT05496335** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 90 (actual)

## Conditions studied

- Glabellar Lines

## Interventions

- **DRUG:** AGN-151586
- **DRUG:** BOTOX
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05496335
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-30
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05496335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05496335, "A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05496335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*